Menu
This week, four pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy"). More
Biogeneric drugmaker Mylan is undergoing soaring growth based on its backlog of generics waiting for U.S government approval to market. Mylan stock is a buy More
This week, four pharmaceutical stocks are improving their overall rating on Portfolio Grader. Each of these rates an "A" ("strong buy") or "B" overall ("buy"). More
As Mary Barra makes history, check out a few other powerful women who beat the odds to become female CEOs of Fortune 500 companies. More
See how the 10 Best Stocks for 2013 stack up heading down the homestretch. Spoiler: A few of these expert picks are clobbering the broader market. More
Another quarter has shaken up our expert picks and left six in the black. Here's how the 10 Best Stocks of 2013 rank heading into the final period. More
Mylan has done its job for short-term traders. Consider taking profits now and live to go long MYL another day. More
Sponsored By:
